### The Oligometastatic Paradigm > [!summary] Key Takeaway > A subset of patients possess limited metastatic burden amenable to complete eradication through systemic therapy and local treatment. The management of colorectal liver metastases (CRLM) fundamentally challenged the traditional view that metastatic cancer is uniformly incurable. While most metastatic solid tumors are treated with palliative intent, carefully selected patients with limited metastatic colorectal cancer can achieve: - Long-term disease-free survival - 10-year survival - Functional cure --- ### What Constitutes "Cure"? This remains controversial. Concepts commonly used include: |Endpoint|Meaning| |---|---| |Overall survival|Most objective endpoint| |Disease-free survival|Time without recurrence| |Recurrence-free survival|Similar to DFS| |Conditional survival|Probability of future survival after surviving a given interval| Practical observations: - Most recurrences occur within 2-3 years - Late recurrences become progressively less common after 5 years - Patients disease-free at 10 years are frequently considered functionally cured Modern series demonstrate: - 5-year OS often 40-60% - 10-year OS approximately 20-30% in selected patients --- ### Initial Evaluation #### Goals Before treatment, determine: 1. Extent of liver disease 2. Presence of extrahepatic disease 3. Technical resectability 4. Biological aggressiveness 5. Molecular profile > [!caution] Essential Takeaway > Early multidisciplinary evaluation and input is key to proper quantification of metastatic burden and sequencing of treatments. --- ### High-Quality Liver Imaging Any patient with known or suspected CRLM should undergo dedicated liver imaging. Preferred studies: - Triphasic liver MRI (often preferred for the most comprehensive understanding) - Triphasic liver CT (often preferred for surgical planning) [[MRI]] is particularly valuable for: - Small lesions - Chemotherapy-treated lesions - Surgical planning - Assessment of future liver remnant > [!note] Real World Nuance > CTs are often initially obtained due to availability, cost, quicker turnaround, and quality. > > MRI quality is more variable / fragile → prone to artifact and improper contrast timing without strict protocols and diligent patients. > > Bottom Line: advocate for early upfront triphasic liver imaging (CT or MRI) in any [[Oligometastatic Colorectal Liver Metastases#Defining High-Risk Disease|high risk patient]]. --- ### Staging Evaluation Typical staging includes: - CT chest - Dedicated liver imaging - Colonoscopy review - CEA Selected patients: - PET/CT - Diagnostic laparoscopy --- ### Defining High-Risk Disease Features associated with aggressive biology include: - T4 primary tumor - Node-positive primary - Synchronous metastases - Multiple liver metastases - Large metastases - Elevated CEA - Early recurrence after treatment - Extrahepatic disease These factors influence: - Perioperative chemotherapy - Surgical timing - Prognosis - Surveillance intensity --- ### Molecular Biology #### Why Molecular Testing Matters > Molecular profiling is increasingly used to inform prognosis, guide resection decisions, prognosticate DFS and OS, and serve as eligibility criteria for clinical trials. > [!done] Practical Takeaway > All patients with metastatic colorectal cancer should undergo comprehensive molecular profiling early in treatment planning. #### RAS (KRAS / NRAS) - Worse DFS and OS - Higher risk of lung recurrence - May influence: - Extent of resection - Margin strategy - Use of anti-EGFR therapy #### BRAF - Particularly: BRAF V600E - Historically considered a relative contraindication to aggressive surgery in some centers, though modern systemic therapies continue to evolve this paradigm. - Associated with: - Aggressive biology - Poor prognosis - Higher rates of systemic failure #### MSI-H / dMMR - Small subset of metastatic CRC. - Implications: - Exceptional response to immunotherapy - Potential alteration of treatment sequencing - Clinical trial eligibility #### HER2 Amplification - Important primarily because targeted therapies now exist. --- ### Determining Resectability Resectability is no longer based solely on: - Number of lesions - Size of lesions - Bilobar disease Instead: > **Can all disease be eradicated while preserving an adequate future liver remnant?** #### Key Questions Can we: - Remove all visible disease? - Ablate selected lesions? - Preserve adequate inflow? - Preserve adequate outflow? - Preserve biliary drainage? - Leave [[Future Liver Remnant|sufficient functional liver]]? --- ### Treatment Sequencing #### Colon First - Resect primary tumor followed by liver-directed therapy. - Historically most common. #### Liver First - Extensive liver disease - Rectal cancer requiring TNT - Liver disease driving prognosis #### Simultaneous Resection - Selected patients. - Advantages: - Single operation - Faster completion of treatment - Limitations: - Increased operative complexity - Not appropriate for all combinations of colorectal and liver resections #### Total Neoadjuvant Approach - Increasingly common. - Benefits: - Tests tumor biology - Treats occult micrometastatic disease - Improves patient selection --- ### Local Therapy #### Hepatectomy - Remains the gold standard when feasible. #### Ablation - Increasingly important. - Particularly for: - Small lesions - Deep lesions - Parenchymal preservation - Related: - [[Ablation|COLLISION Trial]] - [[Ablation Technologies]] #### Combined Resection and Ablation - Common modern strategy. - Allows complete disease clearance while preserving liver volume. #### Hepatic Arterial Infusion Pump Chemotherapy - HAIP therapy occupies a unique role in CRLM management. - Potential uses include: - Conversion therapy - Adjuvant therapy - High-risk resectable disease - Liver-dominant disease --- ### Building a [[Future Liver Remnant]] - When disease is technically resectable but FLR is inadequate, hypertrophy strategies may allow curative treatment. - Options include: - Portal vein embolization (PVE) - Liver venous deprivation - Extended liver venous deprivation - ALPPS - Two-stage or multistage hepatectomy --- ### Surveillance After Curative-Intent Treatment #### Goals - Detect recurrence early - Identify candidates for repeat intervention - Monitor systemic disease #### Typical surveillance includes: - CT imaging - CEA monitoring - Clinical assessment - Circulating Tumor DNA (ctDNA) - Evolving area of interest - Potential applications: - Molecular residual disease detection - Recurrence risk stratification - Earlier recurrence detection - Treatment escalation studies - Current limitations: - Optimal timing remains uncertain - Management implications remain under investigation - Not yet universally incorporated into practice